Pfizer Inc. is weighing options for shedding a group of cardiology, urology and primary care drugs that generate more than $700 million in sales, Bloomberg News reported Feb. 2, citing "people familiar with the matter."

The New York-based drugmaker is reportedly considering selling the treatments as a package. The drugs generate about 40% of their sales from the U.S. and 45% of sales from Europe.

A potential sale could fetch the pharma giant more than $2 billion, according to the unnamed sources, who added that pharmaceuticals and private equity firms might be interested in the portfolio.

The company is working with JPMorgan Chase & Co. as financial advisers for the process, which is still in early stages, Bloomberg News reported.